IBDEI1M7 ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,27398,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27398,1,3,0)
 ;;=3^HTN Hrt & CKD w/o Hrt Failure w/ Stage 1-4 Chr Kidney
 ;;^UTILITY(U,$J,358.3,27398,1,4,0)
 ;;=4^I13.10
 ;;^UTILITY(U,$J,358.3,27398,2)
 ;;=^5007068
 ;;^UTILITY(U,$J,358.3,27399,0)
 ;;=I15.1^^106^1353^11
 ;;^UTILITY(U,$J,358.3,27399,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27399,1,3,0)
 ;;=3^Hypertension Secondary to Oth Renal Disorders
 ;;^UTILITY(U,$J,358.3,27399,1,4,0)
 ;;=4^I15.1
 ;;^UTILITY(U,$J,358.3,27399,2)
 ;;=^5007072
 ;;^UTILITY(U,$J,358.3,27400,0)
 ;;=I15.2^^106^1353^10
 ;;^UTILITY(U,$J,358.3,27400,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27400,1,3,0)
 ;;=3^Hypertension Secondary to Endocrine Disorders
 ;;^UTILITY(U,$J,358.3,27400,1,4,0)
 ;;=4^I15.2
 ;;^UTILITY(U,$J,358.3,27400,2)
 ;;=^5007073
 ;;^UTILITY(U,$J,358.3,27401,0)
 ;;=I50.1^^106^1353^16
 ;;^UTILITY(U,$J,358.3,27401,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27401,1,3,0)
 ;;=3^Left Ventricular Failure
 ;;^UTILITY(U,$J,358.3,27401,1,4,0)
 ;;=4^I50.1
 ;;^UTILITY(U,$J,358.3,27401,2)
 ;;=^5007238
 ;;^UTILITY(U,$J,358.3,27402,0)
 ;;=E26.09^^106^1353^17
 ;;^UTILITY(U,$J,358.3,27402,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27402,1,3,0)
 ;;=3^Primary Hyperaldosteronism,Other
 ;;^UTILITY(U,$J,358.3,27402,1,4,0)
 ;;=4^E26.09
 ;;^UTILITY(U,$J,358.3,27402,2)
 ;;=^5002735
 ;;^UTILITY(U,$J,358.3,27403,0)
 ;;=I15.8^^106^1353^18
 ;;^UTILITY(U,$J,358.3,27403,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27403,1,3,0)
 ;;=3^Secondary Hypertension,Other
 ;;^UTILITY(U,$J,358.3,27403,1,4,0)
 ;;=4^I15.8
 ;;^UTILITY(U,$J,358.3,27403,2)
 ;;=^5007074
 ;;^UTILITY(U,$J,358.3,27404,0)
 ;;=E27.5^^106^1353^1
 ;;^UTILITY(U,$J,358.3,27404,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27404,1,3,0)
 ;;=3^Adrenomedullary Hyperfunction
 ;;^UTILITY(U,$J,358.3,27404,1,4,0)
 ;;=4^E27.5
 ;;^UTILITY(U,$J,358.3,27404,2)
 ;;=^5002744
 ;;^UTILITY(U,$J,358.3,27405,0)
 ;;=E26.01^^106^1353^4
 ;;^UTILITY(U,$J,358.3,27405,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27405,1,3,0)
 ;;=3^Conn's Syndrome
 ;;^UTILITY(U,$J,358.3,27405,1,4,0)
 ;;=4^E26.01
 ;;^UTILITY(U,$J,358.3,27405,2)
 ;;=^329905
 ;;^UTILITY(U,$J,358.3,27406,0)
 ;;=I15.9^^106^1353^19
 ;;^UTILITY(U,$J,358.3,27406,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27406,1,3,0)
 ;;=3^Secondary Hypertension,Unspec
 ;;^UTILITY(U,$J,358.3,27406,1,4,0)
 ;;=4^I15.9
 ;;^UTILITY(U,$J,358.3,27406,2)
 ;;=^5007075
 ;;^UTILITY(U,$J,358.3,27407,0)
 ;;=B20.^^106^1354^3
 ;;^UTILITY(U,$J,358.3,27407,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27407,1,3,0)
 ;;=3^HIV Disease
 ;;^UTILITY(U,$J,358.3,27407,1,4,0)
 ;;=4^B20.
 ;;^UTILITY(U,$J,358.3,27407,2)
 ;;=^5000555
 ;;^UTILITY(U,$J,358.3,27408,0)
 ;;=J18.9^^106^1354^6
 ;;^UTILITY(U,$J,358.3,27408,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27408,1,3,0)
 ;;=3^Pneumonia,Unspec Organism
 ;;^UTILITY(U,$J,358.3,27408,1,4,0)
 ;;=4^J18.9
 ;;^UTILITY(U,$J,358.3,27408,2)
 ;;=^95632
 ;;^UTILITY(U,$J,358.3,27409,0)
 ;;=J10.1^^106^1354^1
 ;;^UTILITY(U,$J,358.3,27409,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27409,1,3,0)
 ;;=3^Flu w/ Respiratory Manifestations
 ;;^UTILITY(U,$J,358.3,27409,1,4,0)
 ;;=4^J10.1
 ;;^UTILITY(U,$J,358.3,27409,2)
 ;;=^5008151
 ;;^UTILITY(U,$J,358.3,27410,0)
 ;;=K52.9^^106^1354^2
 ;;^UTILITY(U,$J,358.3,27410,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27410,1,3,0)
 ;;=3^Gastroenteritis & Colitis,Noninfective,Unspec
 ;;^UTILITY(U,$J,358.3,27410,1,4,0)
 ;;=4^K52.9
 ;;^UTILITY(U,$J,358.3,27410,2)
 ;;=^5008704
 ;;^UTILITY(U,$J,358.3,27411,0)
 ;;=N12.^^106^1354^7
 ;;^UTILITY(U,$J,358.3,27411,1,0)
 ;;=^358.31IA^4^2
